GET DAILY SIGNALSActuate Therapeutics (ACTU): Analyst Target Implies +2,900% Upside Potential
Key Takeaways
- The central target of $9 is the arithmetic mean of five analyst price targets ranging from $5 to $15, collected from H.C. Wainwright, Rodman & Renshaw, Lucid Capital, Craig-Hallum, and B.Riley.
- At the latest verified price near $0.30, reaching $9 would require roughly a 30-fold increase, or about 2,900% upside — an extraordinary move reflecting targets set well before the stock's recent collapse.
- The analyst targets were mostly established between April and September 2026 and have not caught up with the current sub-$0.50 price or the company's Nasdaq minimum bid price deficiency notice.
- Supporting factors include an oral formulation of elraglusib, a U.S. patent allowance, encouraging preclinical melanoma data, and a planned Phase 1/2 trial in early 2027.
- The biggest risks are a tiny cash position, heavy share dilution, delisting risk, and a lead asset that has yet to demonstrate pivotal efficacy in a randomized trial.
- You can explore this ticker's Major News, Today's Price Move, Forecast, and Earnings pages for additional detail.
- For AI-driven trade ideas across thousands of tickers, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Five individual, attributable analyst price targets were reviewed. H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy with a $15 target in September 2026. Rodman & Renshaw's Michael King initiated coverage with a Buy and a $6 target in July 2026. Lucid Capital carries a $5 target (cut from $6 in May 2026), Craig-Hallum maintains $12, and B.Riley holds $8 (lowered from $20 in April 2026). The arithmetic mean is $9.20, rounded to a $9 central target, within a $5 to $15 range.
The wide range reflects genuine disagreement about the value of elraglusib and about the company's ability to fund development. It is important to recognize that these targets were largely set when ACTU traded at $0.80 to $1.80 or higher, and they have not been recalibrated for the recent decline toward all-time lows. As a result, the analyst consensus — generally a "Buy" or "Strong Buy" — is better read as a directional view on the science than as a near-term stock price forecast. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares closed near $0.30 in mid-November 2026, giving the company a market capitalization of only about $16 million. The move to $9 is therefore classified as very large — roughly 30 times the current price — rather than a modest or even substantial gain. The stock has shed roughly 95% over the trailing 12 months, and its 52-week range of $0.29 to $7.90 shows how far the valuation has compressed.
The path back to $9 would almost certainly require a successful, value-creating clinical catalyst combined with substantial new financing. Absent a reverse stock split or a transformative data readout, such a recovery is not supported by the company's current cash position or stage of development.
What Could Support a Move Toward the Target
Actuate has advanced its oral elraglusib program on several fronts. In November 2026 it announced a U.S. Patent and Trademark Office notice of allowance covering oral tablet formulations and presented preclinical data showing the oral tablet inhibited tumor growth and increased CD8+ T-cell and natural killer cell activity in a melanoma model. The FDA cleared the company's Investigational New Drug application in May 2026, and a Phase 1/2 trial of oral elraglusib in advanced solid tumors is planned to begin in the first quarter of 2027. Insider buying by the chief executive in late 2026 also signals management confidence. From what I see, these developments provide some scientific momentum worth monitoring.
What Could Prevent the Target From Being Reached
The obstacles are substantial. The company reported total cash of only about $4.4 million and a trailing net loss of roughly $20 million, raising going-concern and financing questions. Shares outstanding have risen sharply from about 22.9 million at its 2025 offering to roughly 55 million, diluting existing holders. Actuate has received a Nasdaq notice for failing to meet the $1.00 minimum bid price requirement, and a prolonged sub-$1.00 price creates delisting risk. Most fundamentally, elraglusib remains an unproven asset: preclinical and early-stage signals are not yet evidence of clinical benefit, and the next trial is still months from initiation.
Technical Levels and Market Structure
The stock is trading at or near all-time lows, with the 52-week low around $0.29 serving as the nearest support level. There is extensive overhead supply from investors who bought at higher prices across the prior $0.50-to-$7.90 range. The $1.00 level is a meaningful psychological and regulatory threshold, since sustained trading above it would be needed to address the Nasdaq bid price notice. Until the shares can establish a durable base above these lows, the prevailing trend structure remains firmly lower. One thing that stands out here is how the technical picture reinforces the fundamental challenges.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though the dates here span April to September 2026 and the targets may not align with any single unified timeframe. Key items to watch include the next quarterly earnings release and cash-burn update, any additional equity financings and their dilution, progress toward initiating the Phase 1/2 oral elraglusib trial in early 2027, the ENA 2026 poster presentation, and any Nasdaq compliance or delisting developments. I’m watching this closely as the next catalysts could clarify the outlook.
Using AI Tools for Deeper Insight
In my own research, I often turn to Tickeron's AI Daily Buy/Sell Signals to help monitor volatile names like ACTU. These signals use artificial intelligence to continuously track thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a highly volatile name like this, such tools can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual chart review. Traders looking to stay ahead of rapid price changes can explore these AI-driven signals to complement their own research.
Final Assessment
The $9 target is the rounded arithmetic mean of five analyst price targets spanning $5 to $15, but those targets predate a 95% collapse that has left the shares near $0.30. Reaching $9 would require a roughly 30-fold recovery, an outcome that would depend on successful clinical execution, a durable financing solution, and resolution of the Nasdaq listing deficiency. The oral elraglusib program, patent progress, and preclinical data provide a scientific foundation, yet the cash position, dilution, and delisting risk are formidable headwinds. The wide analyst range underscores deep uncertainty, and the path forward hinges on financing and clinical milestones rather than any near-term re-rating.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ACTU's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ACTU turned positive on November 04, 2026. Looking at past instances where ACTU's MACD turned positive, the stock continued to rise in 17 of 18 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACTU advanced for three days, in 89 of 99 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
ACTU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACTU as a result. In 39 of 41 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACTU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ACTU entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.982) is normal, around the industry mean (3.498). P/E Ratio (-0.378) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. ACTU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACTU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement